Filing Details

Accession Number:
0001181431-11-036619
Form Type:
4
Zero Holdings:
No
Publication Time:
2011-06-14 19:19:52
Reporting Period:
2011-06-10
Filing Date:
2011-06-14
Accepted Time:
2011-06-14 19:19:52
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1389870 Omni Bio Pharmaceutical Inc. OMBP Biological Products, (No Disgnostic Substances) (2836) 208097969
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1011938 Mark Steven Bathgate 5350 South Roslyn
Suite 430
Greenwood Village CO 80111
Yes No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2011-06-10 20,000 $0.00 45,000 No 4 P Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 P Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Warrants (Right to Buy) Acquisiton 2011-06-10 20,000 $0.00 20,000 $2.00
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
20,000 2011-06-10 2016-06-10 No 4 P Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 604,000 Indirect By wife
Common Stock 976,750 Indirect By GVC Capital LLC
Common Stock 30,000 Indirect By Bathgate Family Partnership Ltd.
Common Stock 50,000 Indirect By daughter
Footnotes
  1. The reporting person purchased 20,000 Units from the issuer in a private placement transaction for $1.25 per Unit. Each Unit consists of one share of the issuer's common stock and one warrant to purchase one share of the issuer's common stock.
  2. The reporting person disclaims beneficial ownership of these securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of all of such securities for purposes of Section 16 or for any other purpose.
  3. Includes 25,250 shares that were previously reported as being held directly by the reporting person.